Psilocybin-assisted psychotherapy for cancer patients

Psilocybin-assisted psychotherapy, using psilocybin-containing mushrooms or synthetic psilocybin within a therapeutic mindset and environment, may safely and effectively reduce demoralization, death anxiety, and existential distress in patients with serious illness. A case series of advanced cancer patients in Montreal, Canada, who received physician-supervised home-based treatment suggests safety and efficacy. This work, performed outside clinical trials in Quebec's public healthcare system, aimed to provide equitable access and a more patient-centric, culturally-informed approach. However, societal discrimination and stigma, including from healthcare professionals, remain barriers to equitable care, which the authors discuss along with potential solutions.

Study at a glance

Abstract

Despite significant advances in symptom management for patients affected by serious illness, physicians lack effective legal treatments for individuals suffering from demoralization, death anxiety, and existential distress. Psilocybin-assisted psychotherapy employs psilocybin-containing mushrooms or synthetic psilocybin grounded in indigenous traditions and within the context of a therapeutic mindset and environment ("set and setting") to achieve altered states of consciousness that promote healing and psychospiritual growth while reducing suffering. Current research evidence suggests that this form of therapy could serve as a safe and effective therapeutic tool for such patients. This presentation will describe a case series of patients with advanced cancer who received physician-supervised home-based psilocybin-assisted psychotherapy in Montreal, Canada. Our experience postulates the safety and efficacy of this laborious treatment process. By executing this clinical practice in the public healthcare system of Quebec for the first time, we have made an attempt to provide equitable access to these clinical therapies. Having performed these treatments outside the context of clinical trials, we have been able to tailor the therapeutic frame and treatment approach to a more patient-centric and culturally-informed manner. That being said, given the existing ​societal discrimination and stigma against this form of therapy, including by healthcare professionals, there remain further barriers to overcome in the equitable provision of care, especially to certain segments of the population. ​The authors will discuss these and potential solutions to addressing them.